EUCTR2012-002250-23-ES进行中（未招募）不适用
Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer
ovartis Farmaceutica S.A.0 个研究点目标入组 120 人开始时间: 2012年7月26日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced or metastatic castration resistant prostate cancer.
- •Advanced or metastatic castration-resistant prostate cancer progression after abiraterone acetate failure
- •Patients should have no more than 2 lines of prior chemotherapies including cytotoxic agents (i.e. docetaxel)
- •Other protocol defined criteria may apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Previous treatment with PI3K pathway inhibitors (e.g. PI3K, AKT,mTOR inhibitor), ketoconazole, AA or other CYP17 inhibitors (exception of AA), or MDV3100.
- •Patient has active uncontrolled or symptomatic CNS metastases
- •Patients who experienced dose reductions and/or treatment interruptions due to abiraterone acetate related toxicities (i.e. serious AEs, AEs, liver toxicities during abiraterone acetate treatment
研究者
相似试验
已完成
1 期
MAdCaP: MDM2 inhibition and Abiraterone in Carcinoma of the ProstateMalignant neoplasm of prostateCancerProstate cancerISRCTN38949950HS Greater Glasgow and Clyde (UK)132
进行中（未招募）
1 期
A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with mCRCP who have not previously received docetaxel.CancerEUCTR2013-002014-13-GBHS greater Glasgow and Clyde132
尚未招募
不适用
The phaseII study of the efficacy of Abirateron acetate and Dutasteride therapy for castration resistant prostate cancer.castration resistant prostate cancerJPRN-UMIN000027795Department od Urology, Yamaguchi Graduate School of Medicine20
进行中（未招募）
不适用
The study compares the therapy of abiraterone acetate plus LHRH-therapy with the therapy of abiraterone acetate allone in patients with recurrent prostate cancer in spite of chemotherapy and castration, the therapy for every single patient gets select by chanceMedically castrated male patients with chemotherapy-naïve, castration-resistant, metastatic CRPC who have shown tumor progression and are non- or mildly-symptomaticMedDRA version: 16.1Level: LLTClassification code 10066489Term: Progression of prostate cancerSystem Organ Class: 100000004864EUCTR2012-005717-39-DEniversität des Saarlandes
进行中（未招募）
1 期
Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers.EUCTR2014-001274-34-ITFondazione IRCCS Istituto Nazionale dei Tumori24